Extracellular vesicles as new-age vaccine carriers: a focused account on viral diseases - Report - MDSpire

Extracellular vesicles as new-age vaccine carriers: a focused account on viral diseases

  • By

  • Roopali Rajput

  • Madhu Khanna

  • Radhika

  • Jitender Sharma

  • Hardeep Kaur

  • June 19, 2026

  • 0 min

Share

Clinical Report: Extracellular Vesicles as Vaccine Delivery Systems

Overview

Extracellular vesicles (EVs) are carriers for vaccine delivery, capable of presenting viral antigens. This report discusses engineering strategies and applications of EVs in vaccine development against viral infections.

Background

Extracellular vesicles are gaining attention in vaccine development due to their natural origin and ability to protect cargo from degradation. Their capacity to cross biological barriers and present antigens is being explored in the context of viral infections.

Data Highlights

No numerical data available in the source material.

Key Findings

  • EVs can be engineered to present specific proteins and deliver targeted cargo.
  • RSV-infected cell-derived EVs showed enhanced innate immune activation compared to uninfected controls.
  • EVs from FMDV-infected APCs induced virus-specific immunity.
  • DENV- and ZIKV-NS1 dimers carried by EVs have been studied for vaccine potential.
  • EVs can transfer viral components across the blood-brain barrier.

Clinical Implications

Understanding the mechanisms of EVs may enhance the development of targeted therapies and vaccines.

Conclusion

Ongoing research is needed to explore the potential of extracellular vesicles in combating viral diseases.

Related Resources & Content

  1. The Journal of Infectious Diseases, 2023 -- Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration
  2. Journal of Gastroenterology, 2021 -- The Evolving Role and Therapeutic Potential of Exosomes in Hepatitis Virus Infections and Related Conditions
  3. Frontiers in Immunology, 2026 -- Extracellular vesicles in atopic dermatitis: unraveling pathogenic mediators and engineering therapeutic vectors
  4. The Journal of Infectious Diseases — Antibody-Based Antigen Delivery to Dendritic Cells as a Vaccination Strategy Against Ebola Virus Disease
  5. Guidelines and regulatory context for EV-based products
  6. ClinicalTrials.gov - Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19
  7. FDA Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes
  8. Guidance on the clinical application of extracellular vesicles - PMC
  9. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies | Signal Transduction and Targeted Therapy
  10. Outer membrane vesicles as a versatile nanoplatform for advanced vaccine development and immunotherapy
  11. Capricor Therapeutics Announces First Subjects Dosed in
  12. StealthX: A Versatile and Potent Exosome-Based Vaccine Platform for the Next Pandemic - PMC
  13. RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2 | Journal of Nanobiotechnology | Full Text
  14. Inhalable engineered probiotic outer membrane vesicles co-expressing multiple mpox antigens induce potent specific systemic and mucosal immune responses - PubMed
  15. Extracellular vesicles: the double-edged sword in viral infections | mBio

Original Source(s)

Extracellular vesicles as new-age vaccine carriers: a focused account on viral diseases

  • by Roopali Rajput, Madhu Khanna, Radhika, Jitender Sharma, Hardeep Kaur

  • June 19, 2026

Related Content

Personalizing Steroid Duration in Asthma

Researchers tested whether a readily available biomarker can individualize systemic corticosteroid prescribing during asthma-related hospitalizations.

Exercise and tissue-resident memory T cells: from circulating numbers to spatial immune remodeling

Low Follow-Up After Behavioral ED Care

Follow-up occurred after fewer than 15% of mental health ED visits and about 11% of substance use–related visits in Washington Medicaid claims.